

**Supplementary Table 1. Spearman's correlation coefficients calculated for each time-window, separately in cases and controls**

<b>&gt;3 years</b>																
	Controls sCD30	Cases sCD30	Controls sCD27	Cases sCD27	Controls IL6	Cases IL6	Controls CXCL13	Cases CXCL13	Controls IL10	Cases IL10	Controls TNFα	Cases TNFα	Controls Neopterin	Cases Neopterin	Controls IP10	Cases IP10
sCD30	1	1														
sCD27	0.6337*	0.7241*	1	1												
IL6	0.2761*	0.2002*	0.3272*	0.3423*	1	1										
CXCL13	0.4582*	0.5351*	0.4702*	0.5361*	0.2077*	0.2884*	1	1								
IL10	0.2912*	0.1122	0.3102*	0.1564	0.2468*	0.1827*	0.1984*	0.1454	1	1						
TNFα	0.3409*	0.3507*	0.3832*	0.4158*	0.1472	0.2097*	0.2547*	0.2537*	0.4463*	0.062	1	1				
Neopterin	0.4449*	0.4546*	0.5106*	0.5994*	0.2388*	0.2626*	0.3870*	0.4084*	0.1246	0.1128	0.2361*	0.2996*	1	1		
IP10	0.4093*	0.3861*	0.5966*	0.6048*	0.2538*	0.3238*	0.4471*	0.4506*	0.1446	0.1009	0.2741*	0.2996*	0.3986*	0.5238*	1	1
<b>1-3 year</b>																
	Controls sCD30	Cases sCD30	Controls sCD27	Cases sCD27	Controls IL6	Cases IL6	Controls CXCL13	Cases CXCL13	Controls IL10	Cases IL10	Controls TNFα	Cases TNFα	Controls Neopterin	Cases Neopterin	Controls IP10	Cases IP10
sCD30	1	1														
sCD27	0.5804*	0.6884*	1	1												
IL6	0.4147*	0.0514	0.3789*	0.2189*	1	1										
CXCL13	0.5794*	0.4638*	0.4511*	0.5246*	0.2760*	0.2886*	1	1								
IL10	0.3036*	-0.0098	0.2305*	0.0551	0.4025*	0.1996*	0.2423*	0.1839*	1	1						
TNFα	0.2886*	0.4733*	0.3373*	0.5315*	0.0983	0.2692*	0.2508*	0.3463*	0.1789*	0.0756	1	1				
Neopterin	0.5833*	0.3914*	0.4755*	0.4726*	0.3108*	0.2887*	0.4739*	0.4954*	0.1453	0.2008*	0.1475	0.3836*	1	1		
IP10	0.4562*	0.2290*	0.5739*	0.3704*	0.3485*	0.3232*	0.5338*	0.4394*	0.1207	0.0922	0.3216*	0.3039*	0.5386*	0.4840*	1	1
<b>0-1 year</b>																
	Controls sCD30	Cases sCD30	Controls sCD27	Cases sCD27	Controls IL6	Cases IL6	Controls CXCL13	Cases CXCL13	Controls IL10	Cases IL10	Controls TNFα	Cases TNFα	Controls Neopterin	Cases Neopterin	Controls IP10	Cases IP10
sCD30	1	1														
sCD27	0.5542*	0.6818*	1	1												
IL6	0.1603	0.3178*	0.2979*	0.2642*	1	1										
CXCL13	0.4883*	0.4115*	0.3830*	0.4399*	0.2398*	0.1825	1	1								
IL10	0.3715*	0.0626	0.2877*	-0.0395	0.2472*	0.1568	0.2744*	0.2654*	1	1						
TNFα	0.3328*	0.4465*	0.3242*	0.4114*	0.027	0.2423*	0.2914*	0.2691*	0.0796	0.0505	1	1				
Neopterin	0.4348*	0.2364*	0.4027*	0.2378*	0.1327	0.191	0.4100*	0.3407*	0.197	0.3864*	0.2363*	0.3711*	1	1		
IP10	0.4405*	0.1747	0.4982*	0.1097	0.3859*	0.2642*	0.4444*	0.2915*	0.2212*	0.0074	0.2677*	0.3511*	0.4665*	0.2780*	1	1

\* correlation coefficient is significantly different from zero at the 0.05 level

**Supplementary Table 2. Association Between CXCL13 and CXCR5 tagSNPs and CXCL13 Serum Levels**

HUGO gene name	dbSNP reference sequence number	Genotype	N <sup>a</sup>	Mean CXCL13	MR <sup>b</sup>	95% CI
CXCL13	rs1442691	TT	298	108.74	1.00	
		TC	47	121.35	1.12	(0.94-1.34)
		CC	2	114.56	1.05	(0.51-2.22)
CXCL13	rs2053526	AA	126	109.29	1.00	
		AG	146	114.87	1.05	(0.93-1.20)
		GG	70	101.76	0.93	(0.80-1.10)
CXCL13	rs6852819	GG	228	110.05	1.00	
		TG	105	107.71	0.98	(0.87-1.11)
		TT	14	139.73	1.27	(0.96-1.70)
CXCL13	rs17406477	GG	286	112.15	1.00	
		AG	56	105.21	0.94	(0.81-1.10)
		AA	1	104.17	0.93	(0.33-2.64)
CXCL13	rs355679	GG	231	112.80	1.00	
		TG	109	107.65	0.95	(0.85-1.80)
		TT	7	80.43	0.71	(0.48-1.60)
CXCL13	rs2119976	CC	303	112.40	1.00	
		AC	43	100.33	0.89	(0.76-1.60)
CXCL13	rs189587	GG	114	110.23	1.00	
		AG	173	114.07	1.03	(0.92-1.18)
		AA	57	103.09	0.94	(0.79-1.11)
CXCL13	rs355686	CC	217	113.80	1.00	
		TC	120	105.62	0.93	(0.83-1.50)
		TT	8	105.90	0.93	(0.64-1.36)
CXCL13	rs355689	TT	182	111.51	1.00	
		TC	126	107.51	0.97	(0.87-1.11)
		CC	36	94.18	0.82	(0.68-0.99)
CXCL13	rs17002733	CC	285	109.83	1.00	
		TC	55	103.82	1.00	(0.86-1.17)
		TT	5	61.92	0.62	(0.39-1.10)
CXCL13	rs171388	CC	246	106.33		
		CT	78	115.62	1.09	(0.94-1.28)
		TT	22	101.06	0.95	(0.73-1.25)

CXCL13	rs355661	AA	308	110.96	1.00	
		AG	32	113.91	1.03	(0.85-1.26)
		GG	3	101.38	0.91	(0.50-1.68)
CXCL13	rs1052563	TT	290	110.17	1.00	
		TC	48	116.75	1.06	(0.91-1.25)
		CC	7	89.47	0.81	(0.55-1.22)
CXCL13	rs10022693	TT	176	111.42	1.00	
		TC	127	112.73	1.01	(0.90-1.15)
		CC	39	100.55	0.90	(0.74-1.11)
CXCL13	rs17002760	AA	186	110.31		
		AT	125	105.76	0.96	(0.84-1.10)
		TT	28	108.03	0.98	(0.78-1.25)
CXCL13	rs1566485	GG	115	106.00	1.00	
		TG	152	113.92	1.07	(0.95-1.23)
		TT	72	110.69	1.04	(0.89-1.24)
CXCR5	rs11217077	TT	203	112.41	1.00	
		TC	126	106.97	0.95	(0.85-1.80)
		CC	14	123.58	1.10	(0.83-1.47)
CXCR5	rs4938576	GG	129	110.61	1.00	
		TG	159	113.40	1.03	(0.91-1.17)
		TT	55	101.70	0.92	(0.78-1.10)
CXCR5	rs6589706	GG	104	114.42	1.00	
		AG	179	110.24	0.96	(0.85-1.11)
		AA	59	103.51	0.90	(0.77-1.80)
CXCR5	rs11217078	TT	145	110.52	1.00	
		TC	166	109.10	0.99	(0.88-1.12)
		CC	32	118.82	1.08	(0.88-1.32)
CXCR5	rs10892306	TT	304	113.07	1.00	
		TA	37	96.48	0.85	(0.71-1.30)
		AA	2	70.73	0.63	(0.30-1.32)
CXCR5	rs630923	CC	251	108.59	1.00	
		AC	85	105.05	1.00	(0.88-1.14)
		AA	4	223.94	2.40	(1.43-4.50)
CXCR5	rs10892307	CC	238	114.60	1.00	
		GC	93	104.11	0.91	(0.81-1.40)
		GG	10	113.43	0.99	(0.71-1.39)
CXCR5	rs523604	AA	89	108.86	1.00	
		AG	166	110.03	1.01	(0.88-1.17)

		GG	72	116.47	1.07	(0.91-1.27)
CXCR5	rs1623316	CC	133	109.77	1.00	
		GC	151	111.70	1.02	(0.90-1.16)
		GG	54	107.18	0.98	(0.83-1.16)
CXCR5	rs2230321	CC	330	110.21	1.00	
		TC	15	120.64	1.09	(0.83-1.46)
		TT	1	90.49	0.82	
CXCR5	rs3922	TT	103	105.66	1.00	
		TC	172	109.28	1.03	(0.91-1.18)
		CC	65	119.85	1.13	(0.96-1.35)

<sup>a</sup> Number of subjects with at least one and up to three CXCL13 measurements

<sup>b</sup> Mean ratio adjusted for age at AIDS-NHL diagnosis in cases or reference date in controls, absolute CD4<sup>+</sup> T cell counts from each visit where CXCL13 was measured, log<sub>e</sub> HIV viral RNA levels at set point, having an AIDS diagnosis prior to AIDS-NHL diagnosis or reference date, having exposure to HAART prior to AIDS-NHL diagnosis or reference date, and race/ethnicity

**Supplementary Table 3. Association between CXCL13 serum levels and HIV-associated non-Hodgkin lymphoma risk at three time-windows, stratified by SNP genotypes**

SNPs and genotypes	>3 years			1-3 years			0-1 year		
	N	OR <sup>a</sup>	95% CI	N	OR	95% CI	N	OR	95% CI
rs355689									
TT	141	2.21	(1.11-4.42)	157	3.41	(1.54-7.55)	99	8.66	(2.02-37.3)
TC or CC	139	3.02	(1.76-5.19)	125	3.23	(1.86-5.64)	93	4.51	(2.17-9.39)
p-value <sup>b</sup>		0.50			0.92			0.44	
rs17002733									
CC	229	2.48	(1.41-4.37)	234	2.81	(1.55-5.12)	153	4.61	(1.94-11.02)
CT or TT	52	3.04	(1.77-5.23)	50	3.27	(1.88-5.71)	41	4.31	(2.11-8.87)
p-value <sup>b</sup>		0.62			0.72			0.91	
rs630923									
CC	206	2.42	(1.34-4.40)	205	2.87	(1.56-5.32)	132	7.79	(2.84-21.3)
CA or AA	70	2.92	(1.70-5.02)	75	3.15	(1.81-5.51)	59	4.22	(2.07-8.60)
p-value <sup>b</sup>		0.65			0.83			0.34	

OR indicates odds ratio; CI, confidence interval

a. The ORs represent risk of AIDS-NHL associated with one unit increase in log<sub>e</sub> CXCL13. ORs are adjusted for age at AIDS-NHL diagnosis in cases or reference date in controls, absolute CD4<sup>+</sup> T cell counts from each visit where CXCL13 was measured, log<sub>e</sub> HIV viral RNA levels at set point, having an AIDS diagnosis prior to AIDS-NHL diagnosis or reference date, and having exposure to HAART prior to AIDS-NHL diagnosis or reference date

b. P-value for the difference in ORs between each genotype